A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Astellas

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: abatacept

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT01339481

2408-CL-0103

Details and patient eligibility

About

The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.

Enrollment: 26 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Subject has rheumatoid arthritis (RA), is both abatacept- and belatacept-naïve, and is an eligible candidate to start a course of treatment with abatacept in accordance with the product label
• Subject is willing and able to comply with study visits and procedures

Trial design

26 participants in 1 patient group

Subjects with RA initiating abatacept treatment regimen

Description:

Subjects naïve to both abatacept and belatacept

Treatment:

Drug: abatacept